The Russell 2000 trades at a P/E of roughly 37x. Not because a few outliers are dragging the average. Because the index is full of companies that lose money, and when you count them, the "cheap" story collapses. The small-cap opportunity everyone is selling you in 2026 is a valuation trick built on exclusion.
Yes, the S&P 600 looks cheaper at 15.5 to 16x earnings. Of course it does. It screens out the unprofitable companies. That is not a discovery. That is a methodology choice. If you filtered the S&P 500 to exclude its worst earners, it would look cheaper too. The question nobody wants to sit with is what happens to the 40-odd percent of Russell 2000 constituents that don't earn a profit. Those companies still exist. Retail investors still buy them. And the people pitching small-cap value rarely mention how much of the index they're quietly asking you to pretend isn't there.
The Lottery-Ticket Problem
Nektar Therapeutics up 8,375% in a year. AXT Inc up 2,434%. Relmada up 2,400%. These are not evidence of a healthy asset class. They are the return profile of a casino floor where 3 slot machines hit the jackpot and 200 others took your coins. The dispersion in small-cap returns is so extreme that the "average" is meaningless to any individual investor. A retiree in Phoenix who puts $50,000 into a small-cap fund is not getting Nektar. She's getting the basket, and the basket includes a thick layer of companies burning cash with no path to profitability.
I'll grant this: consensus projections of 17 to 22% earnings growth for small caps in 2026 are real, and if they hold, the asset class will look much better by December. But projections are just math applied to management guidance. Small-cap earnings estimates have a dismal track record of surviving contact with actual economic conditions. In 2022, small-cap forward estimates were revised down by over 15% between March and September. Nothing structural has changed about the quality of these forecasts.
The early 2026 numbers look impressive on the surface. The Russell 2000 beat the S&P 500 by more than 5 percentage points year-to-date through mid-March. Micro-caps surged 68% from their April 2025 lows. But Mark Hulbert at MarketWatch has already flagged that this outperformance tracks with seasonal patterns, not durable regime change. Miles Lewis at Royce Investment Partners disagrees, calling 2026 the start of a quality rotation into small caps. I respect Lewis, but Royce manages small-cap money. Their structural incentive is to call the turn every year until they're right once.
What 37x Actually Costs You
Here is what the inflated P/E means in dollar terms. If you invest $10,000 in the Russell 2000 at 37x earnings, you are buying roughly $270 of current earnings. The same $10,000 in the S&P 500 at 23x buys about $435. You need small caps to grow earnings by more than 60% just to reach earnings parity with what you could have bought in large caps today. The projected 17 to 22% growth rate doesn't get you there in 2026. It doesn't get you there in 2027, either.
The last time Wall Street fell in love with small-cap rotation was late 2020 into 2021. The Russell 2000 ripped 20% in 2 months, value stocks surged, and the pitch sounded identical: cheap relative to large caps, earnings catching up, rate environment turning favorable. By mid-2022, the Russell 2000 had given back every point of relative outperformance and then some. The people who bought the rotation paid full price for a thesis that lasted exactly as long as the macro tailwind held.
Small caps are volatile. That alone does not make them a trap. What makes them a trap is when the volatility gets repackaged as opportunity using a filtered index, speculative outliers, and earnings projections that haven't been stress-tested against a single quarter of real economic friction. The Russell 2000 at 37x is not cheap. It is the most expensive way to feel like you're getting a deal.
